Global Uveal Melanoma Therapeutics Market By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea. Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II  study of Nivolumab in combination with Ipilimumab for Uveal Melanoma


Uveal Melanoma Therapeutics Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market


Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Uveal Melanoma Therapeutics Market Segmentation

disease type
  • Choroidal Melanomas
    • o Small Melanomas
    • o Medium-sized Melanomas
    • o Large Melanomas
  • Iris melanomas
  • Ciliary Body Melanomas
Choroidal Melanomas
  • Chemotherapy
    • o Methotrexate
    • o Others
  • Immunotherapy Drugs
    • o Pembrolizumab
    • o Ipilimumab
    • o Others
  • Targeted Drugs
distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Eli Lilly & Co. (U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (UK)
  • Pfizer, Inc. (U.S)
  • Merck (U.S)
  • Roche (Switzerland)
  • Amgen (U.S)
  • Bayer (Germany)
  • Spectrum Pharmaceuticals, Inc. (U.S)